阿替利珠单抗联合贝伐珠单抗治疗肝细胞癌后系统治疗序贯的真实世界分析:IMMUreal队列
基于IMMUreal前瞻性真实世界队列,分析124例2020年6月至2023年12月接受阿替利珠单抗联合贝伐珠单抗一线治疗的肝细胞癌患者。中位总生存期19.8个月,仅41.2%进入二线治疗,19.2%适合三线治疗。基线肝功能较差(Child-Pugh B或ALBI>1)的患者进入二线的概率显著更低,保留肝功能似乎对优化多线治疗至关重要。
要点
- 阿替利珠单抗联合贝伐珠单抗一线治疗后,仅41.2%患者进入二线治疗,19.2%适合三线治疗。
- 真实世界中位总生存期为19.8个月。
- Child-Pugh B或ALBI>1患者进入二线治疗的概率显著更低。
核心结论
- 阿替利珠单抗联合贝伐珠单抗后的序贯治疗仅对部分患者可行,保留肝功能似乎对优化多线治疗和改善晚期肝细胞癌结局至关重要。
研究设计与样本
- 数据来自正在进行的IMMUreal队列,该队列在巴伐利亚两个三级中心研究肝细胞癌的免疫治疗。
- 共分析124例于2020年6月至2023年12月期间接受阿替利珠单抗联合贝伐珠单抗一线治疗的患者。
- 评估序贯治疗的可行性、治疗模式及结局,并聚焦于定义的预后亚组。
主要发现
- 真实世界条件下中位总生存期为19.8个月。
- 41.2%的患者进入二线治疗,仅19.2%适合三线治疗。
- 治疗资格下降与治疗持续时间显著缩短及肝功能进行性恶化相对应,以白蛋白-胆红素(ALBI)和Child-Pugh评分表示。
- 基线肝功能较差(如Child-Pugh B或ALBI>1)的患者进入二线治疗的概率显著更低。
- 治疗线数与肝硬化、体力状况差、肝外疾病或大血管侵犯等因素之间未发现显著关联。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The introduction of several new systemic therapies in recent years has significantly altered the treatment landscape for advanced hepatocellular carcinoma. However, while the approval of the combination of atezolizumab and bevacizumab as the preferred first-line therapy over sorafenib represents progress, it has also raised uncertainties regarding optimal treatment sequencing for advanced disease. AIMS: This study evaluates the sequential treatment of hepatocellular carcinoma following therapy with atezolizumab and bevacizumab, providing evidence from a prospective real-world cohort. METHODS: Data were derived from the ongoing IMMUreal cohort, which investigates immunotherapy in hepatocellular carcinoma across two tertiary centres in Bavaria. A total of 124 patients treated with atezolizumab and bevacizumab as first-line therapy between June 2020 and December 2023 were analysed. Feasibility, treatment patterns, and outcomes of sequential therapy were assessed, with a focus on defined prognostic subgroups. RESULTS: The median overall survival under real-world conditions was 19.8 months. Less than half of the patients (41.2%) proceeded to second-line therapy, and only 19.2% were eligible for third-line treatment. This decline in treatment eligibility corresponded to a marked reduction in therapy duration and progressive deterioration in liver function, as indicated by Albumin-Bilirubin and Child-Pugh scores. While patients with worse baseline liver function, such as patients with Child-Pugh B or ALBI > 1, had a significantly lower probability of transitioning to 2nd line therapy, no significant association was found between the number of treatment lines and factors such as liver cirrhosis, poor physical condition, extrahepatic disease, or macrovascular invasion. CONCLUSIONS: Sequential therapy following atezolizumab and bevacizumab is feasible only for selected patients. However, preserving liver function seems crucial to optimising multi-line therapy and improving outcomes in advanced hepatocellular carcinoma.
引用
- Ben Khaled N, Zarka V, Hobeika B, et al. Therapeutic Sequences of Systemic Therapy After Atezolizumab Plus Bevacizumab for Hepatocellular Carcinoma: Real-World Analysis of the IMMUreal Cohort. Aliment Pharmacol Ther. 2025. PMID: 40181694. doi:10.1111/apt.70090
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。